Last reviewed · How we verify
Vaccination with FLUVAL P
At a glance
| Generic name | Vaccination with FLUVAL P |
|---|---|
| Also known as | Influenza, Pandemic vaccine, Prevention, Influenza vaccine, Influenza in humans |
| Sponsor | Fluart Innovative Vaccine Ltd, Hungary |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Tolerability and Safety Study of FLUVAL P Monovalent Influenza Vaccine in Children (NA)
- Tolerability and Immunogenicity Study of FLUVAL P H1N1 Flu Vaccine of Omninvest in Children and Adolescents (NA)
- Tolerability and Immunogenicity of Fluval P Monovalent Influenza Vaccine (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vaccination with FLUVAL P CI brief — competitive landscape report
- Vaccination with FLUVAL P updates RSS · CI watch RSS
- Fluart Innovative Vaccine Ltd, Hungary portfolio CI